HGEN
Price:
$0.0361
Market Cap:
$4.30M
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is also being studied in conjunction with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Dis...[Read more]
Industry
Biotechnology
IPO Date
2013-01-31
Stock Exchange
NASDAQ
Ticker
HGEN
According to Humanigen, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 0.09. This represents a change of -70.34% compared to the average of 0.32 of the last 4 quarters.
The mean historical Current Ratio of Humanigen, Inc. over the last ten years is 1.46. The current 0.09 Current Ratio has changed 547.03% with respect to the historical average. Over the past ten years (40 quarters), HGEN's Current Ratio was at its highest in in the June 2013 quarter at 7.48. The Current Ratio was at its lowest in in the December 2015 quarter at 0.
Average
1.46
Median
0.39
Minimum
0
Maximum
6.83
Discovering the peaks and valleys of Humanigen, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = Infinity%
Maximum Annual Current Ratio = 6.83
Minimum Annual Increase = -100.00%
Minimum Annual Current Ratio = 0
Year | Current Ratio | Change |
---|---|---|
2022 | 0.20 | -80.86% |
2021 | 1.03 | -69.09% |
2020 | 3.34 | 9.95% |
2019 | 0.03 | -78.85% |
2018 | 0.16 | 150.06% |
2017 | 0.06 | -89.19% |
2016 | 0.58 | Infinity% |
2015 | 0 | -100.00% |
2014 | 2.34 | -65.73% |
2013 | 6.83 | 131.85% |
The current Current Ratio of Humanigen, Inc. (HGEN) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
1.52
5-year avg
0.95
10-year avg
1.46
Humanigen, Inc.’s Current Ratio is less than Acer Therapeutics Inc. (0), less than NRx Pharmaceuticals, Inc. (0.10), less than Pasithea Therapeutics Corp. (0.21), less than SAB Biotherapeutics, Inc. (6.20), less than Windtree Therapeutics, Inc. (5.24), less than Dermata Therapeutics, Inc. (0.23), less than Ensysce Biosciences, Inc. (2.73), less than Panbela Therapeutics, Inc. (1.88), greater than Baudax Bio, Inc. (0.05), greater than Avenue Therapeutics, Inc. (0.07), less than Hoth Therapeutics, Inc. (4.30), less than Revelation Biosciences, Inc. (14.62), less than NeuroBo Pharmaceuticals, Inc. (1.10), less than Virax Biolabs Group Limited (2.94), less than Cardio Diagnostics Holdings, Inc. (25.94), less than NovaBay Pharmaceuticals, Inc. (5.69), less than Oncorus, Inc. (0.62), less than eFFECTOR Therapeutics, Inc. (1.50), less than Apollomics, Inc. (1.03), less than Angion Biomedica Corp. (2.25), less than Sigilon Therapeutics, Inc. (1.74), less than null (1.78),
Company | Current Ratio | Market cap |
---|---|---|
0 | $22.02M | |
0.10 | $17.73M | |
0.21 | $4.37M | |
6.20 | $26.21M | |
5.24 | $1.66M | |
0.23 | $2.08M | |
2.73 | $4.23M | |
1.88 | $1.75M | |
0.05 | $8.13M | |
0.07 | $4.05M | |
4.30 | $7.32M | |
14.62 | $1.43M | |
1.10 | $29.70M | |
2.94 | $15.24M | |
25.94 | $6.94M | |
5.69 | $2.18M | |
0.62 | $3.14M | |
1.50 | $188.18K | |
1.03 | $14.97M | |
2.25 | $30.11M | |
1.74 | $56.22M | |
1.78 | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Humanigen, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Humanigen, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is Humanigen, Inc.'s Current Ratio?
How is the Current Ratio calculated for Humanigen, Inc. (HGEN)?
What is the highest Current Ratio for Humanigen, Inc. (HGEN)?
What is the 3-year average Current Ratio for Humanigen, Inc. (HGEN)?
What is the 5-year average Current Ratio for Humanigen, Inc. (HGEN)?
How does the current Current Ratio for Humanigen, Inc. (HGEN) compare to its historical average?